Compare Cytokinetics Inc (CYTK) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Lockheed Martin Corporation — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Lockheed Martin Corporation trades at $507.89 (market cap $115.22B). The key difference: Lockheed Martin Corporation is far larger — about 13.6× Cytokinetics Inc's market cap, and Lockheed Martin Corporation pays a 2.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Lockheed Martin Corporation for 86 Days on average.
| CYTK | LMT | |
|---|---|---|
Market Cap | $8.50B | $115.22B |
Volume | 2,395,556 | 1,073,075 |
Sector | Health | Industrials |
52-Week High | $87.26 | $676.70 |
52-Week Low | $54.76 | $439.19 |
Typical Hold Time | 19 Days | 86 Days |
Enterprise Value | $8.60B | $131.96B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Lockheed Martin (LMT) trades at $507.89, down 0.44% on the day, with a bearish technical signal driven by moving averages. The stock shows strong profitability with an 8.16% net margin and 89.16% ROE, but recent earnings missed expectations in two of the last three quarters. Revenue growth is steady, projected to reach $77B in 2026, while analyst sentiment remains positive with a $645.50 consensus price target. Recent news highlights dividend increases and AI integration initiatives.
The outlook for LMT is supported by robust defense spending and a high analyst buy rating (59%), but risks include fixed-price contract volatility and debt levels. The stock offers a dividend yield near 0.7% with 23 consecutive years of increases. Upside potential exists if earnings rebound, though technical resistance near $510 may cap near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
